Skip to main content
SpringerLink
Log in

Biological therapy of breast cancer

  • Chapter
Principles of Cancer Biotherapy

  • 1031 Accesses

Several studies indicate that patients with carcinoma of the breast remain reasonably immune competent throughout the natural history of their disease [45, 91]. Anti-tumor immunity is demonstrable in patients by a number of techniques. An in vitro immune reaction to tumor-associated antigens was demonstrated using the leukocyte migration inhibition (LMI) and the leukocyte adherence inhibition (LAI) assays, using as stimulants tumor cell extracts, soluble membrane extracts of MCF-7 cells (a breast cancer cell line), and soluble membrane extracts of biopsy-derived tumor tissue [15, 32, 75]. Several of these studies demonstrated blocking factors, presumably immune complexes, in the serum [83]. The T-antigen, a precursor of the M and N blood group antigens whose expression is masked on normal tissue, is expressed on nearly all breast carcinoma tissue. Patients also mount a strong cellular immune reaction to this antigen as demonstrated by both delayed hypersensitivity and in vitro LMI. The demonstration of delayed hyper-sensitivity to tumor-associated antigens has not been particularly useful clinically. However 85% of breast cancer patients had such a reaction to a crude membrane extract prepared from cultured MCF-7 breast tumor cells previously infected with vesicular stomatitis virus [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aisner J, Weinberg V, Perloff M, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/− MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol 1987;5:1523–1533.

    CAS  Google Scholar 

  2. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259–267.

    Article  CAS  PubMed  Google Scholar 

  3. Austin FC, Boone CW, Levin DL, et al. Breast cancer skin test antigens of increased sensitivity prepared from vesicular stomatitis virus-infected tumor cells. Cancer 1982;49:2034–2042.

    Article  CAS  PubMed  Google Scholar 

  4. Bartsch R, Wenzel C, Altorjai G, et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007;102:375–381.

    Article  CAS  PubMed  Google Scholar 

  5. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing meta-static breast cancer. J Clin Oncol 1996;14:737–744.

    CAS  PubMed  Google Scholar 

  6. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162–2171.

    Article  CAS  PubMed  Google Scholar 

  7. Bonnem EM, Spiegel RJ. Interferon-alpha: current status and future promise. J Biol Response Mod 1984;3:580–598.

    CAS  PubMed  Google Scholar 

  8. Borden EC, Holland JF, Dao TL, et al. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med 1982;97:1–6.

    CAS  Google Scholar 

  9. Burris H 3rd, Yardle D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22:1621–1629.

    Article  CAS  PubMed  Google Scholar 

  10. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing meta-static breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003a;21:2889–2895.

    Article  CAS  Google Scholar 

  11. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003b;21:46–53.

    Article  CAS  Google Scholar 

  12. Buzaid AC, Blumenschein GR, Hortovagyi GN. Adjuvant chemotherapy with 5-fluorouracil doxorubicin (Adriamycin) and cyclo-phosphamide, with or without BCG immunotherapy in stage II or stage III breast cancer. In. Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982:175–181.

    Google Scholar 

  13. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–3685.

    Article  CAS  PubMed  Google Scholar 

  14. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophos-phamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228–233.

    Article  CAS  PubMed  Google Scholar 

  15. Cannon B, McCoy JL, Connor RJ, et al. Use of the leukocyte migration inhibition assay to evaluate antigenic differences in human breast cancers and melanomas. J Natl Cancer Inst 1978;60:969–978.

    CAS  PubMed  Google Scholar 

  16. Carpenter JT Jr, Smalley RV, Raney M, et al. Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70:1073–1079.

    PubMed  Google Scholar 

  17. Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006;95:788–793.

    Article  CAS  PubMed  Google Scholar 

  18. Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxo-rubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773–2778.

    Article  CAS  PubMed  Google Scholar 

  19. Chiesa MD, Passalacqua R, Michiara M, et al. Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multi-centre trial. Acta Biomed 2007;78:204–209.

    PubMed  Google Scholar 

  20. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexperessing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.

    CAS  PubMed  Google Scholar 

  21. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117–124.

    Article  CAS  PubMed  Google Scholar 

  22. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and car-boplatin for human epidermal growth factor receptor-2-overex-pressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007;25:2678–2684.

    Article  CAS  PubMed  Google Scholar 

  23. De Maio E, Pacilio C, Gravina A, et al. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer 2007;7:50.

    Article  PubMed  Google Scholar 

  24. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358–2370.

    Article  CAS  PubMed  Google Scholar 

  25. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289–1297.

    CAS  PubMed  Google Scholar 

  26. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800–1808.

    Article  CAS  PubMed  Google Scholar 

  27. Fennelly DW, Norton L, Sznol M, Hakes TB. A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer. Cancer 1995;75:2099–2102.

    Article  CAS  PubMed  Google Scholar 

  28. Fentiman IS, Balkwill FR, Cuzick J, et al. A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence. Eur J Surg Oncol 1987;13:425–428.

    CAS  PubMed  Google Scholar 

  29. Fer MF, Oldham RK. An immunoadsorption/immunoactivation: a critical review. Immune complexes and human cancer. New York: Plenum, 1985:257–276.

    Google Scholar 

  30. Fisher B, Brown A, Wolmark N, et al. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer 1990;66:220–227.

    Article  CAS  PubMed  Google Scholar 

  31. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001;12:1545–1551.

    Article  CAS  PubMed  Google Scholar 

  32. Fujisawa T, Waldman SR, Yonemoto RH. Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients. Cancer 1977;39:506–513.

    Article  CAS  PubMed  Google Scholar 

  33. Gilewski TA, Ragupathi G, Dickler M, et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res 2007;13:2977–2985.

    Article  CAS  PubMed  Google Scholar 

  34. Gori S, Colozza M, Mosconi AM, et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004;90:36–40.

    Article  CAS  PubMed  Google Scholar 

  35. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980;93:399–406.

    CAS  PubMed  Google Scholar 

  36. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 2004;3:655–663.

    Article  CAS  PubMed  Google Scholar 

  37. Holohan TV, Phillips TM, Bowles C, Deisseroth A. Regression of canine mammary carcinoma after immunoadsorption therapy. Cancer Res 1982;42:3663–3668.

    CAS  PubMed  Google Scholar 

  38. Hortobagyi GN, Buzdar AU, Frye D, et al. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer 1987;60:2596–2604.

    Article  CAS  PubMed  Google Scholar 

  39. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastu-zumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831–1838.

    Article  CAS  PubMed  Google Scholar 

  40. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002;7:410–417.

    Article  CAS  PubMed  Google Scholar 

  41. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant doc-etaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820.

    Article  CAS  PubMed  Google Scholar 

  42. Lacour J, Lacour F, Spira A, et al. Adjuvant treatment with poly-adenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Br Med J (Clin Res Ed) 1984;288:589–592.

    Article  CAS  Google Scholar 

  43. Klefstrom P, Holsti P, Grohn P, et al. Levamisole in the treatment of stage II breast cancer. Five-year follow-up of a randomized double-blind study. Cancer. 1985;55:2753–2757.

    Article  CAS  PubMed  Google Scholar 

  44. Klefstrom P, Nuortio L. Levamisole in the treatment of advanced breast cancer. A ten-year follow-up of a randomized study. Acta Oncol 1991;30:347–352.

    Article  CAS  PubMed  Google Scholar 

  45. Krown SE, Pinsky CM, Wanebo HJ, et al. Immunologic reactivity and prognosis in breast cancer. Cancer 1980;46:1746–1752.

    Article  CAS  PubMed  Google Scholar 

  46. Laszlo J, Hood L, Cox E, Goodwin B. A randomized trial of low doses of alpha interferon in patients with breast cancer. J Biol Response Mod 1986;5:206–210.

    CAS  PubMed  Google Scholar 

  47. Lentz MR. Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Mod 1989;8:511–527.

    CAS  PubMed  Google Scholar 

  48. Leyland-Jones B, Gelmon K, Ayoub J P, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965–3971.

    Article  CAS  PubMed  Google Scholar 

  49. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43–49.

    Article  CAS  PubMed  Google Scholar 

  50. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–4274.

    Article  CAS  PubMed  Google Scholar 

  51. Messerschmidt GL, Henry DH, Snyder HW Jr, et al. Protein A immunoadsorption in the treatment of malignant disease. J Clin Oncol 1988;6:203–212.

    CAS  PubMed  Google Scholar 

  52. McCulloch PB, Poon M, Dent PB, Dawson P. A stratified randomized trial of 5-flurouracil, doxorubicin (Adriamycin) and cyclo-phosphamide alone or with BCG in stage IV breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier, 1982:183–186.

    Google Scholar 

  53. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–2676.

    Article  CAS  PubMed  Google Scholar 

  54. Miller KD, Sisk J, Ansari R, et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 2001;15(2 Suppl 3):38–40.

    CAS  PubMed  Google Scholar 

  55. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792–799.

    Article  CAS  PubMed  Google Scholar 

  56. Mohsin Sk, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastu-zumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460–2468.

    Article  CAS  PubMed  Google Scholar 

  57. Montemurro F, Choa G, Faggiuolo R, et al. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. Am J Clin Oncol 2003;26:95–97.

    Article  CAS  PubMed  Google Scholar 

  58. Morabito A, Longo R, Gattuso D, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep 2006;16:393–398.

    CAS  PubMed  Google Scholar 

  59. Murphy RM, Colton CK, Yarmush ML, et al. Staphylococcal protein A adsorption in neoplastic disease: analysis of physicochemi-cal aspects. Mol Biother 1989;1:186–206.

    CAS  PubMed  Google Scholar 

  60. Oldham R. Symposium on ex vivo plasma immunoabsorption and protein A in cancer therapy. J Biol Resp Modif 1984;3:229–230.

    Google Scholar 

  61. Oldham RK. Biologicals for cancer treatment: interferons. Hosp Pract 1985;20:72–91.

    Google Scholar 

  62. Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination chemotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer. Mol Biother 1991;3:68–73.

    CAS  PubMed  Google Scholar 

  63. O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5:142–147.

    Article  PubMed  Google Scholar 

  64. Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006;17:630–636.

    Article  CAS  PubMed  Google Scholar 

  65. Park JW, Melisko ME, Esserman LJ, et al. Treatment with autolo-gous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 2007;25:3680–3687.

    Article  CAS  PubMed  Google Scholar 

  66. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.

    CAS  PubMed  Google Scholar 

  67. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759–769.

    Article  CAS  PubMed  Google Scholar 

  68. Perez Ea, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;6:425–432.

    Article  CAS  PubMed  Google Scholar 

  69. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.

    Article  CAS  PubMed  Google Scholar 

  70. Ray PK, Raychaudhuri S, Allen P. Mechanism of regression of mammary adenocarcinomas in rats following plasma adsorption over protein A-containing Staphylococcus aureus. Cancer Res 1982;42:4970–4974.

    CAS  PubMed  Google Scholar 

  71. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786–2792.

    Article  CAS  PubMed  Google Scholar 

  72. Rojas AF, Feierstein JN, Mickiewicz E, et al. Levamisole in advanced human breast cancer. Lancet 1976;1:211–215.

    Article  CAS  PubMed  Google Scholar 

  73. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.

    Article  CAS  PubMed  Google Scholar 

  74. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 patients. Ann Surg 1989;210:474–485.

    Article  CAS  PubMed  Google Scholar 

  75. Rudczynski AB, Dyer CA, Mortensen RF. Detection of cell-mediated immune reactivity of breast cancer patients by the leukocyte adherence inhibition response to MCF-7 extracts. Cancer Res 1978;38:3590–3594.

    CAS  PubMed  Google Scholar 

  76. Sato N, Sano M, Tabei T, et al. Combination docetaxel and trastu-zumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer 2006;13:166–171.

    Article  PubMed  Google Scholar 

  77. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587–2595.

    CAS  PubMed  Google Scholar 

  78. Senn HJ, Barett-Mahler AR, Jungi WF, et al. Adjuvant chemoim-munotherapy with Leukeran, Methotrexate and 5FU (LMF) + BCG in node-negative and node-positive breast cancer patients: 10 year results. Eur J Cancer Clin Oncol 1989;25:513–525.

    Article  CAS  PubMed  Google Scholar 

  79. Serrou B, Sancho-Garnier H, Cappelaere P. Inefficacy of post radiotherapeutic BCG immunotherapy in T3-T4 breast cancer patients: a randomized trial. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier, 1982: 195–198.

    Google Scholar 

  80. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

    Article  CAS  PubMed  Google Scholar 

  81. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastu-zumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.

    Article  CAS  PubMed  Google Scholar 

  82. Stemmler HJ, Kahlert S, Brudler O, et al. High efficacy of gemcit-abine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clin Oncol 2005;17:630–635.

    Article  CAS  Google Scholar 

  83. Tanaka F, Yonemoto RH, Waldman SR. Blocking factors in sera of breast cancer patients. Cancer 1979;43:838–847.

    Article  CAS  PubMed  Google Scholar 

  84. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3 + overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004;22:1071–1077.

    Article  CAS  PubMed  Google Scholar 

  85. Terman DS. Protein A and staphylococcal products in neoplastic disease. Crit Rev Oncol Hematol 1985;4(2):103–124.

    Article  CAS  PubMed  Google Scholar 

  86. Terman DS, Yamamoto T, Mattioli M, et al. Extensive necrosis of spontaneous canine mammary adenocarcinoma after extra-corporeal perfusion over Staphylococcus aureus Cowans I. Description of acute tumoricidal response: morphologic, histologic, immunohistochemical, immunologic, and serologic findings. J Immunol 1980;124:795–805.

    CAS  PubMed  Google Scholar 

  87. Terman DS, Young JB, Shearer WT, et al. Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. N Engl J Med 1981;305:1195–1200.

    Article  CAS  PubMed  Google Scholar 

  88. Vahdat LT, Cohen DJ, Zipin D, et al. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after highdose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant 2007;40:267–272.

    Article  CAS  PubMed  Google Scholar 

  89. Venturini M, Bighin C, Monfardini S, et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2006;95:45–53.

    Article  CAS  PubMed  Google Scholar 

  90. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.

    Article  CAS  PubMed  Google Scholar 

  91. Weese J, Oldham RK, Tormey DC. Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet 1997;145:208–218.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hoag Cancer Center, Newport Beach, CA, USA

    Robert O. Dillman

  2. University of California, Irvine, CA, USA

    Robert O. Dillman

Authors
  1. Robert O. Dillman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hematology-Oncology Associates of Southeast Missouri Hospital, Southeast Medical Plaza, Cape Girardeau, MO, USA

    Robert K. Oldham

  2. Hoag Cancer Center, Newport Beach, CA, USA

    Robert O. Dillman

  3. University of California, Irvine, CA, USA

    Robert O. Dillman

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Dillman, R.O. (2009). Biological therapy of breast cancer. In: Oldham, R.K., Dillman, R.O. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2289-9_25

Download citation

Publish with us

Policies and ethics

Search

Navigation